



UNITED Scientific
Group
A non-profit organization



Fifth International Conference on
**Cancer Research
and Drug
Development**
(Virtual)



OCTOBER 26-28, 2020

Sponsor:



9-854-2280/81

<https://cancer.unitedscientificgroup.org/>



Day

October 26

08:30-09:00
Zoom Meeting Joining
and Welcome

08:30-09:00 Zoom Meeting Joining and Welcome

Plenary Talk

09:00-09:45 **Title: Using Networks to Understand Cancer Risk**
John Quackenbush, Harvard TH Chan School of Public Health, Channing Division of Network Medicine, and Dana-Farber Cancer Institute, MA

Session: Immunotherapy in Cancer

Chair: Eduardo Davila, University of Colorado CU Comprehensive Cancer Center, CO

09:45-10:15 **Title: Oncolytic Reagents may also Enhance Anti-Tumor Immunity by Inducing MyD88-dependent Maturation of Dendritic Cells**
Joost J. Oppenheim, NIH/NCI, MD

10:15-10:45 **Title: Overcoming a Frequent Inborn Immune Defect in Breast Cancer Therapy**
Guido Kroemer, Gustave Roussy Comprehensive Cancer Center, INSERM, France

10:45-11:00 Break

11:00-11:30 **Title: Versamune (R-DOTAP): a Transformative Cationic Lipid Nanoparticle Technology Associated with Type I Interferon Specific Activation and Generation of Antibody, CD8 and CD4 T Cell Responses to Recombinant Proteins and Peptide Tumor Antigens**
Lauren V. Wood, Chief Medical Officer, PDS Biotechnology, NJ

11:30-11:55 **Title: Tumor-Derived Exosomes and Their Role in Cancer Progression**
Theresa L. Whiteside, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, PA

11:55-12:20 **Title: Title to be updated**
Scott K. Durum, NCI/CCR, NIH, MD

12:20-12:45 **Title: Novel Gene Platforms to Maintain the Persistence and Antitumor Activity of TIL-, CAR-, and DC-Based Therapies**
Eduardo Davila, University of Colorado CU Comprehensive Cancer Center, CO

12:45-13:10 Lunch

13:10-13:35 **Title: UNITE Platform, A Direct Antigen Presentation Approach in Oncology**
William Hearl, Ph.D. CEO, Immunomic Therapeutics, MD

13:35-14:00 **Title: Dual Antagonism of Prostaglandin Receptors EP2 and EP4 by TPST-1495 Suppresses Tumor Growth and Stimulates Antitumor Immunity**
Brian Francica, Tempest Therapeutics, CA

14:00-14:25 **Title: MHC Class-I Independent Activation of Virtual-Memory CD8 T Cells Induced by Chemotherapeutic Agent-Treated Cancer Cells**
Jing H. Wang, University of Colorado Anschutz Medical Campus, CO

14:25-14:50 **Title: SA-4-1BBL, a novel immune checkpoint agonist, invokes an innate immune surveillance mechanism with long-term protective efficacy against various tumor types**
Haval Shirwan, FasCure Therapeutics, LLC, Louisville, KY

14:50-15:00	Break
15:00-15:25	Title: The MAPK/ERK-regulated MEF-2 isoforms as potential new target(s) for HTLV-1 induced Adult T-cell leukemia/lymphoma (ATLL) Pooja Jain , Drexel University College of Medicine, Philadelphia, PA
15:25-15:50	Title: Performance Optimization of a Novel HPV VLP Vaccine in Mice with Novel Adjuvants Jason D. Marshall , Leidos Biomedical Research, Inc., NCI Campus at Frederick, MD
15:50-16:15	Title: Duality of NO in Melanoma Joseph Markowitz , Moffit Cancer Center, FL
16:15-16:40	Title: Metabolic Requirements for T Cell Protein Translation in Tumors Jessica E. Thaxton , Medical University of South Carolina, SC
16:40-17:05	Title: Finetune Your CARs: Building the Next Generation of Anti-Cancer Therapies Yan Leyfman , Penn State College of Medicine, PA

E - POSTERS

E-P01	Title: Evaluating The Correlation Between Aspirin Consumption And The Risk Of Developing Actinic Keratosis Maximiliano Guerra , Holy Cross Hospital, Michael and Dianne Bienes Comprehensive Cancer Center, Florida
E-P02	Title: Evaluating The Risk Of Thiazides And ACE Inhibitors Exposure And Cutaneous Malignant Neoplasm Jason Shao , Holy Cross Hospital, Michael and Dianne Bienes Comprehensive Cancer Center, Florida
E-P03	Title: Evaluating The Correlation Between Folic Acid Exposure And The Risk Of Developing Actinic Keratosis Ana Gabriela Santizo Orellana , Holy Cross Hospital, Michael and Dianne Bienes Comprehensive Cancer Center, Florida
E-P04	Title: Evaluating the Risk of Thiazide and Angiotensin Converting Enzyme Inhibitors Exposure and Squamous Cell Carcinoma Development Amalia Ardeljan , Holy Cross Hospital, Michael and Dianne Bienes Comprehensive Cancer Center, Florida

Concluding Remarks for the day



Day

October 27

08:30-09:00
Zoom Meeting Joining
and Welcome

08:30-09:00 Zoom Meeting Joining and Welcome

Session: New Concepts and Potential Chemotherapy for Treatment & Prevention of Cancers Symposium

Chairs: Leslie C. Costello, University of Maryland, Greenebaum Comprehensive Cancer Center, MD
Renty B. Franklin, University of Maryland School of Dentistry, MD

09:00-09:25 **Title:** To be Updated
Vincent C. O. Njar, Marlene and Stewart Greenebaum Comprehensive Cancer Center; University of Maryland School of Medicine, MD

09:25-09:50 **Title:** Therapeutic Potential of Antidiabetic Biguanides in Oral Oncology
Abraham Schneider, University of Maryland School of Dentistry Greenebaum Comprehensive Cancer Center, MD

09:50-10:15 **Title:** Transcriptional Characterization of de novo Chemo-Refractory Acute Myeloid Leukemia
Sachi Horibata, NCI/NIH, MD

10:15-10:30 Break

10:30-11:10 **Title:** To be Updated
Leslie C. Costello, University of Maryland, Greenebaum Comprehensive Cancer Center, MD

11:10-11:40 **Title:** The Role of Cellular Metabolism in the Pathogenesis of Prostate Cancer
Renty B. Franklin, University of Maryland School of Dentistry, MD

11:40-11:50 Concluding Remarks

12:00-12:30 Lunch Break

Session: Industry Symposium
Transport and Metabolism in Drug Development

Chairs: Yan Zhang, Director, Nuvation Bio, NY
Jason Boer, Director, Incyte Corporation, DE

12:40-13:10 **Title:** Interplay of Transporters and Drug-Metabolizing Enzymes in Drug Disposition and Interaction: Scientific and Industry Perspectives
Hong Shen, Bristol Myers Squibb, NJ

13:10-13:40 **Title:** Title to be updated
Xinning Yang, CDER, FDA

13:40-14:10 **Title:** Title to be updated
Kenneth R. Brouwer, Vice President, Technology - ADME-TOX, BioIVT

14:10-14:40 **Title:** Novel in vitro Human Hepatic and Enteric Systems for the Evaluation of Drug Uptake, Metabolism, and Toxicity
Albert Li, In Vitro ADMET Laboratories Inc., Columbia, MD and Malden, MA

14:40-14:50 Break

14:50-15:20 **Title: Atypical Metabolic Pathways and Associated DDI/Toxicity**
Jason Boer, Director, Incyte Corporation, DE

15:20-15:50 **Title: Metabolism and DDI/Tox in Cancer Drug Development**
Cyrus Khojasteh

15:50-16:20 **Title: Metabolism Based Drug Interactions: Impact on Co-dosing**
Michael Mohutsky

E - POSTERS

E-P01 **Title: Evaluation of the Correlation Between Angiotensin Receptor Blocker and Risk of Actinic Keratosis**
Divesh Manjani, Holy Cross Hospital, Michael and Dianne Bienes Comprehensive cancer center, Florida

E-P02 **Title: An Evaluation Of The Correlation Between Aspirin Consumption And Basal Cell Carcinoma Development**
Lexi Frankel, Holy Cross Hospital, Michael and Dianne Bienes Comprehensive Cancer Center, Florida

E-P03 **Title: Examining The Correlation Between Folic Acid Exposure And The Risk Of Developing Basal Cell Carcinoma**
Kishan Shingala, Holy Cross Hospital, Michael and Dianne Bienes Comprehensive Cancer Center, Florida

E-P04 **Title: Evaluating The Correlation Between Angiotensin Converting Inhibitor Exposure And Development Of Basal Cell Carcinoma**
Stephanie Shimon, Holy Cross Hospital, Michael and Dianne Bienes Comprehensive Cancer Center, Florida

E-P05 **Title: Urinary Metabolites in Canine Mammary Gland Tumors**
Marcela Valko-Rokytovska, University of Veterinary Medicine and Pharmacy in Košice, Komenského, Slovak Republic



Day

October 28

8:30-9:00
Zoom Meeting Joining
and Welcome

08:30-09:00 Zoom Meeting Joining and Welcome

09:00-09:30 Plenary Talk

Title: Metabolic Reprogramming in Cancer: The Bridge that Connects Intracellular pH Stress and Cancer Behaviors
Ying Xu, The University of Georgia, GA

Session: Discussions on Cancer Metabolism, Metastasis and Targeted Therapy

09:30-09:35 Welcome of Chairs

Chairs: William P. Schieman, Case Comprehensive Cancer Center, Case Western Reserve University, OH
William H. Gmeiner, Wake Forest University, NC

09:35-10:00 **Title:** Development of Two Monoclonal Antibodies Targeting the Interleukin-7 Receptor for Leukemia Treatment
Scott T.R. Walsh, CCR/NCI/NIH, MD

10:00-10:25 **Title:** Improved Efficacy and Reduced Systemic Toxicity of the Polymeric Fluoropyrimidine CF10 in Pre-Clinical Models of Colorectal Cancer
William H. Gmeiner, Wake Forest University, NC

10:25-10:35 Break

10:35-11:00 **Title:** Acquired Deficiency of the Peroxisomal Enzyme Enoyl-CoA Hydratase/3-Hydroxyacyl CoA Dehydrogenase (Ehhadh) is a Metabolic Vulnerability in a Mouse Model of Hepatoblastoma
Edward V. Prochownik, UPMC Children's Hospital of Pittsburgh, PA

11:00-11:25 **Title:** SLX4IP and Telomere Dynamics Dictate Breast Cancer Metastasis and Therapy Response
William P. Schieman, Case Comprehensive Cancer Center, Case Western Reserve University, OH

11:25-11:50 **Title:** Enhancing Chemotherapeutic Efficacy in Colon Cancer through Serine Deprivation
David C. Montrose, Stony Brook University, NY

11:50-12:10 **Title:** Hyaluronic acid receptor-RHAMM mediates Renal Carcinoma Metastasis
Heriberto Moran, The City College of The City University of New York, NY

12:10-12:30 **Title:** Understanding the Diverse Role of Fibronectin in Breast Cancer Metastasis
Luis Solorio, Purdue University, IN

Plenary Talk

12:30-12:55 **Title:** Identification of Novel Epigenetic Targets in Thoracic Malignancies Using Induced Pluripotent Stem Cell Models
David S. Schrupp, National Cancer Institute, MD

12:55-13:25 Lunch

Session: Breast Cancer

13:25-13:30 Welcome of Chairs

Chairs: Yan Peng, UT Southwestern Medical Center Dallas, TX USA
Xingyi Guo, Vanderbilt University Medical Center, TN

- 13:30-13:50** **Title:** MLN4924 Inhibits Growth and Enhances Cisplatin-Induced Cytotoxicity of Triple Negative Breast Cancer by Inhibiting Nucleotide Excision Repair Pathway
Alo Ray, The Ohio State University, Columbus, OH
- 13:50-14:10** **Title:** Breast Cancer Tumor Biomarkers: Issues in Clinical Practice
Yan Peng, UT Southwestern Medical Center Dallas, TX
- 14:10-14:30** **Title:** Discovery of Susceptibility Gene in Breast Cancer
Xingyi Guo, Vanderbilt University Medical Center, TN
- 14:30-14:50** **Title:** Optimising the Murine 4T1 Model of Breast Cancer for Peri-Operative Research
Helen C. Gallagher, School of Medicine, Conway Institute for Biomolecular and Biomedical Research, University College Dublin, Dublin 4, and UCD-Mater Clinical Research Centre, Ireland
- 14:50-15:10** **Title:** Metabolically Targeting Epithelial-Mesenchymal Plasticity of Breast Cancer Stem Cells
Ming Luo, University of Michigan, MI

15:10-15:20 **Break**

Session: **Novel Therapeutic Targets in Cancer; Cancer Drug Development
Heredity and Cancer Genomics; Tumor Microenvironment**

15:20-15:25 **Welcome of Chairs**

15:25-15:45 **Title:** Long-Read Sequencing of Human Transcription
Jianhua Luo, University of Pittsburgh Medical Center, PA

15:45-16:05 **Title:** IGM-8444 is a Potent Agonistic Death Receptor 5 (DR5) IGM Antibody with Broad Clinical Potential
Eric W. Humke, IGM Biosciences Inc, USA

16:05-16:25 **Title:** Modeling and Targeting Stromal-Tumor Crosstalk in Tumor Microenvironment
Stephen T. C. Wong, Houston Methodist, Weill Cornell Medical College, TX

16:25-16:50 **Title:** The Thomsen Friedenreich Tumor-Associated Carbohydrate Antigen in Anticancer Nanoparticle Drug Discovery
Joseph J. Barchi Jr, NIH/NCI, MD

16:50-17:15 **Title:** Light-Sensitive Cancer Nanomedicine for On-Demand Delivery of Anti-cancer Agents and RNAi Therapeutics
Anu Puri, National Cancer Institute-Frederick, National Institutes of Health, MD

17:15-17:25 **Break**

17:25-17:50 **Title:** Anthracycline-Induced Conformational Changes of P-glycoprotein during Transport
Arthur G Roberts, The University of Georgia College of Pharmacy, GA

17:50-18:15 **Title:** Interleukin-17 in Colorectal Cancer and Immunity
Kepeng Wang, UConn Health, CT

18:15-18:40 **Title:** DDX5 Promotes Oncogene C3 and FABP1 Expressions and Drives Intestinal Inflammation and Tumorigenesis
Wendy Jia Men Huang, University of California San Diego, CA

18:40-19:05 **Title:** Hypoxia Suppresses Lysosomal Activity and Receptor Tyrosine Kinase Degradation
Jaewoo Hong, CCR/NCI/NIH, MD

19:05-19:30 **Title:** Using natural cytotoxic diterpenoids for innovative nanosystems
Patrícia Rijo, Universidade Lusófona de Humanidades e Tecnologias, Portugal

Contact:

Kinnera Kalagara

Conference Manager-Cancer R&D 2020

Email: kkalagara@uniscigroup.net

For Organizing Committee

USG United Scientific Group (A non-profit organization)

8105, Suite 112, Rasor Blvd, PLANO, TX 75024; **Tel:** +1 469-854-2281

Web: <https://cancer.unitedscientificgroup.org/>; **LinkedIn:** <https://www.linkedin.com/in/kinnera-kalagara-612600118/>; **Twitter:** @KK_usgcancer